325 related articles for article (PubMed ID: 18596385)
1. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
[TBL] [Abstract][Full Text] [Related]
2. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
[TBL] [Abstract][Full Text] [Related]
3. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
5. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
8. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
9. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
[TBL] [Abstract][Full Text] [Related]
10. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E
Melanoma Res; 2000 Jun; 10(3):237-41. PubMed ID: 10890377
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients.
Vereecken P; Awada A; Suciu S; Castro G; Morandini R; Litynska A; Lienard D; Ezzedine K; Ghanem G; Heenen M
Melanoma Res; 2009 Oct; 19(5):316-20. PubMed ID: 19581819
[TBL] [Abstract][Full Text] [Related]
12. A single-institution validation of the AJCC staging system for stage IV melanoma.
Neuman HB; Patel A; Ishill N; Hanlon C; Brady MS; Halpern AC; Houghton A; Coit DG
Ann Surg Oncol; 2008 Jul; 15(7):2034-41. PubMed ID: 18465172
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
14. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
15. Serum markers in skin melanoma--preliminary study.
Dumitraşcu G; Constantin C; Manda G; Hristescu S; Mărgaritescu I; Chiriţă D; Neagu M
Roum Arch Microbiol Immunol; 2009; 68(3):125-35. PubMed ID: 20361532
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
17. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
[TBL] [Abstract][Full Text] [Related]
19. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
Helfrich I; Edler L; Sucker A; Thomas M; Christian S; Schadendorf D; Augustin HG
Clin Cancer Res; 2009 Feb; 15(4):1384-92. PubMed ID: 19228739
[TBL] [Abstract][Full Text] [Related]
20. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]